Licensing opportunity
Newly formed speciality pharmaceuticals company EUSA Pharma Ltd, of Oxford, UK wants to divest three pre-clinical compounds for treating central nervous system diseases: TKP1001 for treating Alzheimer’s disease; TKP1002, an anti-psychotic; and 3,4 DAP for treating multiple sclerosis. The company says this in line with its strategy of focusing on sourcing products close to market in the areas of oncology, pain and critical care.
EUSA Pharma was formed in May 2006, and in March 2007 raised $170 million to fund the acquisition of the biotech company OPi SA of Lyon, France.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
